8-K: Lilly to Acquire Adverum Biotechnologies for Up to $12.47/Share

Eli Lilly and Company announced a definitive agreement to acquire Adverum Biotechnologies, Inc. for an upfront cash payment and contingent value rights tied to its lead gene therapy candidate, Ixo-vec.

Summary

• Eli Lilly and Company will acquire Adverum Biotechnologies, Inc. through a tender offer and subsequent merger.
• Adverum shareholders will receive $3.56 per share in cash at closing, plus one non-tradable Contingent Value Right (CVR) per share.
• Each CVR represents the contractual right to receive up to two contingent cash payments totaling up to $8.91, bringing the total potential consideration to $12.47 per share.
• The first CVR milestone payment of up to $1.78 per CVR is contingent on U.S. regulatory approval of Ixo-vec for wet age-related macular degeneration (wAMD) prior to the seventh anniversary of the closing date.
• The second CVR milestone payment of up to $7.13 per CVR is contingent on Ixo-vec achieving annual worldwide net sales exceeding $1.0 billion prior to the tenth anniversary of the closing date.
• A Milestone Offset Amount of up to $0.50 per CVR may be deducted from milestone payments for necessary intellectual property licensing.
• Eli Lilly will provide Adverum with up to $65.0 million in secured debt financing via a Promissory Note to fund working capital and Ixo-vec clinical development until the transaction closes.
• Adverum's board of directors unanimously approved the transaction, following an evaluation of strategic alternatives, and recommends shareholders tender their shares.

Sentiment

Score: 8

Explanation: The acquisition provides a substantial premium and potential upside for Adverum shareholders, while also securing the future development of its lead asset, Ixo-vec, under a major pharmaceutical company. The interim financing addresses immediate liquidity concerns. However, the non-tradable nature of CVRs and the lack of 'Commercially Reasonable Efforts' for the larger sales milestone introduce some uncertainty and limit immediate realization of full value.

Positives

• Shareholders receive an immediate cash payment of $3.56 per share, providing a certain return.
• Potential for significant additional value through CVRs, totaling up to $8.91 per CVR, linked to Ixo-vec's regulatory and commercial success.
• The acquisition provides Adverum with critical interim financing of up to $65.0 million, addressing its immediate cash needs (expected to finance only October 2025 operations otherwise).
• Ixo-vec, Adverum's lead gene therapy candidate, has received Fast Track, Regenerative Medicine Advanced Therapy (RMAT) from the U.S. FDA, PRIME from the EMA, and Innovation Passport from the UK MHRA, indicating strong regulatory recognition of its potential.
• The transaction offers a clear path for Ixo-vec's continued development and potential commercialization under Eli Lilly's substantial resources and expertise.

Negatives

• CVRs are non-tradable, limiting liquidity and the ability for shareholders to realize potential upside before milestones are met.
• Achievement of CVR milestones is uncertain and subject to various risks, including regulatory approvals and commercial success, with no guarantee of payment.
• Eli Lilly has no obligation to use 'Commercially Reasonable Efforts' to achieve the Second Milestone (net sales exceeding $1.0 billion), potentially reducing the likelihood of the larger CVR payment.
• The Promissory Note is secured by substantially all of Adverum's assets, including intellectual property, and becomes immediately due upon termination of the merger agreement, posing a significant risk if the deal fails.
• Out-of-the-money stock options will be cancelled for no consideration if not exercised prior to the Effective Time.

Risks

• Uncertainties regarding the timing and completion of the tender offer and merger.
• The possibility that competing offers or acquisition proposals for Adverum will be made.
• The risk that various closing conditions for the Offer or Merger, or for financing under the Promissory Note, may not be satisfied or waived.
• Difficulty in predicting the timing or outcome of regulatory approvals or actions for Ixo-vec.
• The possibility that CVR milestone payments may never be achieved, or if achieved, the amount may be reduced by the Milestone Offset Amount.
• Risks related to the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including failures or delays in clinical trials.
• Negative effects of the announcement or consummation of the proposed transaction on Adverum's common stock market price and/or operating results.
• Significant transaction costs and unknown or inestimable liabilities.
• The risk of litigation and/or regulatory actions related to the proposed transaction.
• Adverum's obligations under the Secured Promissory Note and its ability to satisfy such obligations, including the risk of acceleration upon a Triggering Event.
• Adverum's cash sufficiency and runway, and its ability to continue as a going concern without the advances from the Promissory Note.

Future Outlook

Eli Lilly aims to accelerate the innovative medicine Ixo-vec to patients, leveraging its scientific depth and global reach. Adverum's management expresses excitement about joining Lilly to advance their vision of delivering a transformative 'One and Done' therapy for wAMD. The future outlook for Ixo-vec is tied to achieving U.S. regulatory approval and significant worldwide net sales, which are the basis for the contingent value rights.

Management Comments

• "We are eager to welcome Adverum colleagues to Lilly and to help accelerate this innovative medicine to patients." Andrew Adams, Lilly group vice president, Molecule Discovery.
• "We are excited about the potential to join Lilly, with a proven track record in the discovery, development, and commercialization of innovative medicines for chronic and age-related conditions." Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
• "We share Lillys commitment to healthy aging and genetic medicines innovation. Their scientific depth and global reach offer the opportunity to accelerate our vision to deliver a transformative One and Done therapy that can potentially restore and preserve vision for millions of patients living with wAMD." Laurent Fischer, M.D.
• "My deepest appreciation goes out to the entire Adverum team for their expertise, creativity and commitment. We are also grateful to the investigators, patients and caregivers who have contributed to the success of Ixo-vec thus far." Laurent Fischer, M.D.

Industry Context

This acquisition reflects a broader trend in the pharmaceutical industry where large, established companies like Eli Lilly are acquiring clinical-stage biotechnology firms to bolster their pipelines, particularly in high-growth and innovative areas like gene therapy. The focus on wet age-related macular degeneration (wAMD) highlights the significant unmet need for more convenient and potentially curative treatments for chronic ocular diseases, moving beyond frequent injections. Lilly's move into gene therapy for age-related diseases aligns with a strategic shift towards advanced therapeutic modalities and addressing conditions associated with an aging global population.

Comparison to Industry Standards

• The deal structure, combining an upfront cash payment with contingent value rights (CVRs), is a common approach in biotech acquisitions, especially for clinical-stage assets, allowing the acquirer to share risk and align incentives with the acquired company's shareholders on future product success.
• The CVRs being non-tradable is a standard feature in many such deals, which limits immediate liquidity for shareholders but simplifies the CVR administration.
• The provision of interim financing via a secured promissory note is a critical, but also common, mechanism to ensure the acquired company can maintain operations and advance its lead candidate until the acquisition closes, particularly when the target company has limited cash runway.
• The termination fee of $4.0 million, representing a small percentage of the total potential deal value, is within typical industry ranges for transactions of this size.
• The 'Commercially Reasonable Efforts' clause for the first CVR milestone is standard, but the absence of such a clause for the second, larger milestone (net sales) is notable and potentially less favorable to Adverum shareholders compared to some other CVR agreements.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Receive upfront cash and potential future contingent payments via CVRs, offering a premium over pre-announcement value and participation in Ixo-vec's success.
• Employees: Adverum colleagues will be welcomed to Lilly, with commitments for base salary/wage rate and target cash incentive compensation opportunities at least as favorable for 12 months, and substantially comparable broad-based benefits.
• Customers/Patients: Ixo-vec's development and potential commercialization will be accelerated under Lilly's resources, potentially leading to a transformative 'One and Done' therapy for wAMD patients.
• Creditors: The Promissory Note provides secured debt financing, ensuring Adverum's operations continue, but also creates a first-priority lien on assets.
• Management: Adverum's CEO, Laurent Fischer, expresses appreciation for the team and excitement for the potential to join Lilly. Directors are expected to resign.

Next Steps

• Purchaser (Flying Tigers Acquisition Corporation) will commence a tender offer for Adverum shares.
• Adverum will file a Solicitation/Recommendation Statement on Schedule 14D-9.
• The transaction is expected to close in the fourth quarter of 2025, subject to closing conditions, including the tender of a majority of outstanding shares.
• Following the tender offer, a second-step merger will occur to acquire any untendered shares.
• Eli Lilly will continue the development of Ixo-vec, aiming for U.S. regulatory approval for wet age-related macular degeneration.
• Adverum will terminate its Sales Agreement with Cowen and Company, LLC within five business days of the agreement date.
• Adverum will receive advances under the Promissory Note on specified dates (October 28, November 7, November 21, December 5, 2025).

Key Dates

Recommendation

The definitive merger agreement provides Adverum shareholders with a fixed cash payment and potential additional value through non-tradable CVRs. Given the unanimous board approval and recommendation to tender shares, existing shareholders should hold their shares to participate in the tender offer and subsequent merger. The offer price, including potential CVRs, represents a favorable outcome, especially considering Adverum's previously limited cash runway.

Keywords

Adverum Biotechnologies, Eli Lilly, Merger, Acquisition, Gene Therapy, Ixo-vec, Wet Age-Related Macular Degeneration, wAMD, Contingent Value Rights, CVR, Tender Offer, Biotechnology, Pharmaceuticals, Promissory Note, Clinical Trials, Regulatory Approval